FX.co ★ Alnylam Pharmaceuticals Inc. Q3 Earnings Summary

Alnylam Pharmaceuticals Inc. (ALNY) has disclosed its earnings for the third quarter. The company reported a net loss of $111.57 million, a stark contrast to the $147.75 million profit recorded in the same quarter of the previous year. This translates to a loss per share (EPS) of $0.87, compared to an EPS of $1.15 during the same period last year. On an adjusted basis, taking into account certain items, the company posted a loss of $64.20 million or $0.50 per share. This was more favorable than analysts' expectations, who predicted a loss of $0.93 per share. Revenue for the third quarter reached $420.146 million, a notable increase from the $313.153 million recorded in the corresponding quarter of the previous year.